212 related articles for article (PubMed ID: 29169562)
21. Treatment of severely itchy scalp psoriasis and palmoplantar pustulosis with unsatisfied response to secukinumab, adalimumab or ustekinumab using upadacitinib: A report of two cases.
Hu W; Wang Y; Zhang S; Wu X; Lian C
J Dermatol; 2024 May; 51(5):e151-e153. PubMed ID: 38031884
[No Abstract] [Full Text] [Related]
22. Efficacy and safety of brodalumab in patients with psoriasis who had inadequate responses to ustekinumab: subgroup analysis of two randomized phase III trials.
Langley RG; Armstrong AW; Lebwohl MG; Blauvelt A; Hsu S; Tyring S; Rastogi S; Pillai R; Israel R
Br J Dermatol; 2019 Feb; 180(2):306-314. PubMed ID: 30328108
[TBL] [Abstract][Full Text] [Related]
23. Complete response of secukinumab in palmoplantar psoriasis.
Rocamora V; Garcías-Ladaria J
Dermatol Online J; 2017 Oct; 23(10):. PubMed ID: 29469799
[TBL] [Abstract][Full Text] [Related]
24. Successful treatment of ustekinumab in a severe psoriasis patient with human immunodeficiency virus infection.
Saeki H; Ito T; Hayashi M; Fukuchi O; Umezawa Y; Nobeyama Y; Teruya K; Nakagawa H
J Eur Acad Dermatol Venereol; 2015 Aug; 29(8):1653-5. PubMed ID: 24754476
[No Abstract] [Full Text] [Related]
25. Cost-effectiveness of secukinumab as first biologic treatment, compared with other biologics, for moderate to severe psoriasis in Germany.
Augustin M; McBride D; Gilloteau I; O'Neill C; Neidhardt K; Graham CN
J Eur Acad Dermatol Venereol; 2018 Dec; 32(12):2191-2199. PubMed ID: 29729105
[TBL] [Abstract][Full Text] [Related]
26. Cost per additional responder for ixekizumab and other FDA-approved biologics in moderate-to-severe plaque psoriasis.
Al Sawah S; Foster SA; Burge R; Amato D; Schacht A; Zhu B; Hartz S; Leonardi C
J Med Econ; 2017 Dec; 20(12):1224-1230. PubMed ID: 28760056
[TBL] [Abstract][Full Text] [Related]
27. Ustekinumab in patients previously treated with TNFα inhibitors: a real-life study.
Pinheiro RR; Duarte B; Ferreira A; Cabete J
Eur J Dermatol; 2018 Feb; 28(1):89-91. PubMed ID: 29400282
[No Abstract] [Full Text] [Related]
28. Combination of antitumour necrosis factor-α and anti-interleukin-12/23 antibodies in refractory psoriasis and psoriatic arthritis: a long-term case-series observational study.
Gniadecki R; Bang B; Sand C
Br J Dermatol; 2016 May; 174(5):1145-6. PubMed ID: 26522308
[No Abstract] [Full Text] [Related]
29. Spotlight on ustekinumab in moderate to severe plaque psoriasis.
Croxtall JD
Am J Clin Dermatol; 2012 Apr; 13(2):135-7. PubMed ID: 22201419
[TBL] [Abstract][Full Text] [Related]
30. Effectiveness and safety of secukinumab in 69 patients with moderate to severe plaque psoriasis: A retrospective multicenter study.
Schwensen JF; Clemmensen A; Sand C; Gniadecki R; Skov L; Zachariae C; Iversen L; Rasmussen M; Thomsen SF
Dermatol Ther; 2017 Nov; 30(6):. PubMed ID: 28906051
[TBL] [Abstract][Full Text] [Related]
31. Secukinumab in multi-failure psoriatic patients: the last hope?
Magnano M; Loi C; Patrizi A; Sgubbi P; Balestri R; Rech G; Tasin L; Girardelli CR; Conti A; Odorici G; Campanati A; Offidani AM; Bardazzi F
J Dermatolog Treat; 2018 Sep; 29(6):583-585. PubMed ID: 29334270
[TBL] [Abstract][Full Text] [Related]
32. Switching from Secukinumab to Ustekinumab in Psoriasis Patients: Results from a Multicenter Experience.
Chiricozzi A; Conti A; Burlando M; Odorici G; Gaiani F; Panduri S; Malagoli P
Dermatology; 2019; 235(3):213-218. PubMed ID: 30928971
[TBL] [Abstract][Full Text] [Related]
33. Ustekinumab in severe complicated erythrodermic psoriasis: rapid clearing, safety, and sustained remission.
Koutsoukou XA; Papadavid E; Theodoropoulos K; Rigopoulos D
Dermatol Ther; 2014; 27(5):257-9. PubMed ID: 24813816
[TBL] [Abstract][Full Text] [Related]
34. No need to change the drug class: ixekizumab- following secukinumab-therapy in psoriasis.
Bokor-Billmann T; Schäkel K
J Dermatolog Treat; 2019 May; 30(3):216-220. PubMed ID: 30051725
[TBL] [Abstract][Full Text] [Related]
35. Ustekinumab induces rapid clearing of erythrodermic psoriasis after failure of antitumour necrosis factor therapies.
Santos-Juanes J; Coto-Segura P; Mas-Vidal A; Galache Osuna C
Br J Dermatol; 2010 May; 162(5):1144-6. PubMed ID: 20222926
[No Abstract] [Full Text] [Related]
36. Switching to Interleukin-23 Inhibitors After Ineffectiveness of Ustekinumab: Evaluating Real-World Outcomes in Psoriasis Treatment.
Thomas SE; Seyger MMB; Mangnus JE; Otero ME; Gostynski AH; Njoo MD; Ossenkoppele PM; Haeck IM; Hendricksen-Roelofzen JHJ; Körver JEM; Dodemont SRP; Tupker RA; Berends MAM; Weppner-Parren LMJT; Keijsers RRMC; Oostveen AM; Peters B; Mommers R; van Doorn MBA; Tjioe M; Veldkamp WR; Kuijpers ALA; Kleinpenning MM; de Jong EMGJ; van den Reek JMPA
Am J Clin Dermatol; 2024 Jul; 25(4):685-688. PubMed ID: 38802618
[No Abstract] [Full Text] [Related]
37. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial.
Reich K; Papp KA; Blauvelt A; Langley RG; Armstrong A; Warren RB; Gordon KB; Merola JF; Okubo Y; Madden C; Wang M; Cioffi C; Vanvoorden V; Lebwohl M
Lancet; 2021 Feb; 397(10273):487-498. PubMed ID: 33549193
[TBL] [Abstract][Full Text] [Related]
38. Treatment of psoriasis with ustekinumab in a patient with HIV-related Kaposi sarcoma.
Wang DM; Fernandez AP; Calabrese CM; Calabrese LH
Clin Exp Dermatol; 2019 Jan; 44(1):113-115. PubMed ID: 29797733
[No Abstract] [Full Text] [Related]
39. Comparison of the cost-effectiveness of biologic drugs used for moderate-to-severe psoriasis treatment in the United States.
Wu JJ; Feldman SR; Rastogi S; Menges B; Lingohr-Smith M; Lin J
J Dermatolog Treat; 2018 Dec; 29(8):769-774. PubMed ID: 29658383
[TBL] [Abstract][Full Text] [Related]
40. IL-17 inhibitors for psoriasis.
Paek SY; Frieder J; Kivelevitch D; Menter MA
Semin Cutan Med Surg; 2018 Sep; 37(3):148-157. PubMed ID: 30215631
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
